Literature DB >> 28836006

Management of superior vena cava syndrome in critically ill cancer patients.

Sarah Morin1, Adeline Grateau1, Danielle Reuter1, Eric de Kerviler2,3, Constance de Margerie-Mellon2, Cédric de Bazelaire2,3, Lara Zafrani1,3, Benoit Schlemmer1,3, Elie Azoulay1,3, Emmanuel Canet4.   

Abstract

PURPOSE: The purpose of this study is to describe the management and outcome of critically ill cancer patients with Superior Vena Cava Syndrome (SVCS).
METHODS: All cancer patients admitted to the medical intensive care unit (ICU) of the Saint-Louis University Hospital for a SVCS between January 2004 and December 2016 were included.
RESULTS: Of the 50 patients included in the study, obstruction of the superior vena cava was partial in two-thirds of the cases and complete in one-third. Pleural effusion was reported in two-thirds of the patients, pulmonary atelectasis in 16 (32%), and pulmonary embolism in five (10%). Computed tomography of the chest showed upper airway compression in 18 (36%) cases, while echocardiography revealed 22 (44%) pericardial effusions. The causes of SVCS were diagnosed one (0-3) day after ICU admission, using interventional radiology procedures in 70% of the cases. Thirty (60%) patients had hematological malignancies, and 20 (40%) had solid tumors. Fifteen (30%) patients required invasive mechanical ventilation, seven (14%) received vasopressors, and renal replacement therapy was implemented in three (6%). ICU, in-hospital, and 6-month mortality rates were 20, 26, and 48%, respectively. The cause of SVCS was the only factor independently associated with day 180 mortality by multivariate analysis. Patients with hematological malignancies had a lower mortality than those with solid tumors (27 versus 80%) (odds ratio 0.12, 95% confidence interval (0.02-0.60), p < 0.01).
CONCLUSION: Airway obstruction and pleural and pericardial effusions contributed to the unstable condition of cancer patients with SVCS. The vital prognosis of SVCS was mainly related to the underlying diagnosis.

Entities:  

Keywords:  Acute respiratory failure; Cancer; Intensive care unit; Superior vena cava syndrome; Supportive care

Mesh:

Year:  2017        PMID: 28836006     DOI: 10.1007/s00520-017-3860-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  36 in total

Review 1.  Image-guided needle biopsy for diagnosis and molecular biology in lymphomas.

Authors:  E de Kerviler; C Benet; J Brière; C de Bazelaire
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-25       Impact factor: 3.020

Review 2.  Evidence-based focused review of management of hyperviscosity syndrome.

Authors:  Marvin J Stone; Steven A Bogen
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

3.  Risk of Critical Illness Among Patients With Solid Cancers: A Population-Based Observational Study.

Authors:  Kathryn Puxty; Philip McLoone; Tara Quasim; Billy Sloan; John Kinsella; David S Morrison
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

Review 4.  Managing critically Ill hematology patients: Time to think differently.

Authors:  Elie Azoulay; Frédéric Pène; Michael Darmon; Etienne Lengliné; Dominique Benoit; Marcio Soares; Francois Vincent; Fabrice Bruneel; Pierre Perez; Virginie Lemiale; Djamel Mokart
Journal:  Blood Rev       Date:  2015-04-26       Impact factor: 8.250

Review 5.  Oncologic mechanical emergencies.

Authors:  Umar A Khan; Carl B Shanholtz; Michael T McCurdy
Journal:  Emerg Med Clin North Am       Date:  2014-06-07       Impact factor: 2.264

Review 6.  Image-guided biopsy in primary lung cancer: Why, when and how.

Authors:  C de Margerie-Mellon; C de Bazelaire; E de Kerviler
Journal:  Diagn Interv Imaging       Date:  2016-07-29       Impact factor: 4.026

7.  Subacute and chronic benign superior vena cava obstructions: endovascular treatment with self-expanding metallic stents.

Authors:  S D Qanadli; M El Hajjam; F Mignon; E de Kerviler; P Rocha; O Barré; S Chagnon; P Lacombe
Journal:  AJR Am J Roentgenol       Date:  1999-07       Impact factor: 3.959

8.  Long-term results of endovascular stent placement in the superior caval venous system.

Authors:  T Smayra; P Otal; V Chabbert; P Chemla; M Romero; F Joffre; H Rousseau
Journal:  Cardiovasc Intervent Radiol       Date:  2001-10-17       Impact factor: 2.740

Review 9.  Acute Thoracic Findings in Oncologic Patients.

Authors:  Brett W Carter; Jeremy J Erasmus
Journal:  J Thorac Imaging       Date:  2015-07       Impact factor: 3.000

10.  Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure: A Randomized Clinical Trial.

Authors:  Virginie Lemiale; Djamel Mokart; Matthieu Resche-Rigon; Frédéric Pène; Julien Mayaux; Etienne Faucher; Martine Nyunga; Christophe Girault; Pierre Perez; Christophe Guitton; Kenneth Ekpe; Achille Kouatchet; Igor Théodose; Dominique Benoit; Emmanuel Canet; François Barbier; Antoine Rabbat; Fabrice Bruneel; Francois Vincent; Kada Klouche; Kontar Loay; Eric Mariotte; Lila Bouadma; Anne-Sophie Moreau; Amélie Seguin; Anne-Pascale Meert; Jean Reignier; Laurent Papazian; Ilham Mehzari; Yves Cohen; Maleka Schenck; Rebecca Hamidfar; Michael Darmon; Alexandre Demoule; Sylvie Chevret; Elie Azoulay
Journal:  JAMA       Date:  2015-10-27       Impact factor: 56.272

View more
  2 in total

1.  Successful stent implantation in a rural area on a patient with superior vena cava syndrome through specialist intervention: a case report.

Authors:  Yusuke Watanabe; Kenichi Sakakura; Honoka Kotoku; Shota Mashimo; Maiko Nakata; Hiroyuki Nagata; Yoshiro Chiba; Masayuki Kojima
Journal:  J Rural Med       Date:  2019-05-30

2.  Long-term survival of a patient with an inoperable thymic neuroendocrine tumor stage IIIa under sole treatment with Viscum album extract: A CARE compliant clinical case report.

Authors:  María Reynel; Yván Villegas; Paul G Werthmann; Helmut Kiene; Gunver S Kienle
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.